ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för glasdegib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2019-09-13

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA.

Future Oncol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.2217/fon-2019-0373

Bibliografisk träff 2019-09-01

Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.

Goldsmith SR, Lovell AR, Schroeder MA.

Drugs Today (Barc) · journal article · DOI 10.1358/dot.2019.55.9.3020160

Bibliografisk träff 2019-08-21

Glasdegib in the treatment of acute myeloid leukemia.

Wolska-Washer A, Robak T.

Future Oncol · clinical trial, phase ii; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.2217/fon-2019-0171

Bibliografisk träff 2019-05-07

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.

Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, Shen YL, Sheth CM, Liu C, Leong R, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1158/1078-0432.ccr-19-0365

Bibliografisk träff 2019-04-12

Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.

Shaik N, Hee B, Liang Y, LaBadie RR.

Clin Pharmacol Drug Dev · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.692

Bibliografisk träff 2019-03-30

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2019.03.008

Bibliografisk träff 2019-02-28

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.leukres.2019.02.012

Bibliografisk träff 2019-02-01

Glasdegib: First Global Approval.

Hoy SM.

Drugs · review; journal article · DOI 10.1007/s40265-018-1047-7

Bibliografisk träff 2018-12-16

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M.

Leukemia · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1038/s41375-018-0312-9

Bibliografisk träff 2018-12-10

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.

Shaik N, Hee B, Wei H, LaBadie RR.

Cancer Chemother Pharmacol · equivalence trial; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-018-3748-8

Bibliografisk träff 2018-09-09

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.

Am J Hematol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/ajh.25238

Bibliografisk träff 2018-04-10

Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.

Shaik MN, Hee B, Wei H, LaBadie RR.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1111/bcp.13568

Bibliografisk träff 2018-02-20

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-17-2824

Bibliografisk träff 2017-10-30

Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.

Giri N, Lam LH, LaBadie RR, Krzyzaniak JF, Jiang H, Hee B, Liang Y, Shaik MN.

Cancer Chemother Pharmacol · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-017-3472-9

Bibliografisk träff 2017-06-19

Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.

Minami Y, Minami H, Miyamoto T, Yoshimoto G, Kobayashi Y, Munakata W, Onishi Y, Kobayashi M, Ikuta M, Chan G, Woolfson A, Ono C, Shaik MN, Fujii Y, Zheng X, Naoe T.

Cancer Sci · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/cas.13285

Bibliografisk träff 2017-01-03

Metabolism, excretion and pharmacokinetics of [<sup>14</sup>C]glasdegib (PF-04449913) in healthy volunteers following oral administration.

Lam JL, Vaz A, Hee B, Liang Y, Yang X, Shaik MN.

Xenobiotica · clinical trial, phase i; journal article · DOI 10.1080/00498254.2016.1261307

Bibliografisk träff 2016-08-01

The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.

Giordani G, Barraco M, Giangrande A, Martinelli G, Guadagnuolo V, Simonetti G, Perini G, Bernardoni R.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.10879

Bibliografisk träff 2015-07-26

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C.

Lancet Haematol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/s2352-3026(15)00096-4

Bibliografisk träff 2014-11-11

A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.

Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB.

Clin Cancer Res · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-14-1116

Bibliografisk träff 2014-06-19

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.

Shaik MN, LaBadie RR, Rudin D, Levin WJ.

Cancer Chemother Pharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-014-2502-0

Bibliografisk träff 2011-12-21

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.

Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml2002423